Gates Foundation moves to cut HIV infections with low-cost injection
The Bill & Melinda Gates Foundation has struck a new deal with Indian pharmaceutical company, Hetero Labs, to produce a low-cost generic version of lenacapavir, the world’s first twice-yearly injectable HIV prevention drug. The foundation will provide upfront funding and volume guarantees to Hetero, enabling the drug to be sold at about $40 per patient…